Literature DB >> 339932

Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

W H Perks, S S Chatterjee, R S Croxson, J M Cruickshank.   

Abstract

1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction. 2 In patients with "fixed" airways obstruction, neither atenolol nor exprenolol significantly affected airways resistance. 3 In patients with "labile" airways obstruction, atenolol did not produce a significant increase in airways obstruction, whereas oxprenolol did. 4 Following isoprenaline challenge (1500 microgram by inhalation), atenolol permitted full bronchodilatation, whereas oxprenolol almost completely blocked the action of isoprenaline. 5 Partial agonist activity appears to be of less clinical importance than cardioselectivity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 339932      PMCID: PMC1429247          DOI: 10.1111/j.1365-2125.1978.tb01608.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Metabolic studies on oxprenolol in animals and man by means of radio-tracer techniques and GLC-analysis.

Authors:  W Riess; T G Rajagopalan; P Imhof; K Schmid; H Keberle
Journal:  Postgrad Med J       Date:  1970-11       Impact factor: 2.401

2.  Beta-adrenergic blocking drugs.

Authors:  J W Paterson
Journal:  Br Med J       Date:  1971-06-12

3.  Practolol in the treatment of tachyarrhythmias in patients with bronchial asthma.

Authors:  H Formgren
Journal:  Am Heart J       Date:  1972-11       Impact factor: 4.749

4.  The beta-blocking effect of practolol in asthmatics.

Authors:  C Bernecker; I Roetscher
Journal:  Lancet       Date:  1970-09-26       Impact factor: 79.321

5.  Cardiac and pulmonary effects of acebutolol.

Authors:  C R Kumana; C M Kaye; M Leighton; P Turner; J Hamer
Journal:  Lancet       Date:  1975-07-19       Impact factor: 79.321

6.  Practolol treatment in asthmatics.

Authors:  H J Waal-Manning; F O Simpson
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

7.  Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris.

Authors:  H Aström; H Vallin
Journal:  Br Heart J       Date:  1974-12

8.  Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.

Authors:  G Johnsson; N Svedmyr; G Thiringer
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

9.  Comparison of the effect of alprenolol and propranolol on specific airway conductance in asthmatic subjects.

Authors:  C K Connolly; J C Batten
Journal:  Br Med J       Date:  1970-05-30

10.  Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.

Authors:  F J Conway; J D Fitzgerald; J McAinsh; D J Rowlands; W T Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more
  22 in total

1.  Comparative beta-adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diacetolol on the human isolated bronchus.

Authors:  E Naline; B Sarria; O Ertzbischoff; P Ozanne; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

3.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

4.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  V M Oh; C M Kaye; S J Warrington; E A Taylor; J Wadsworth
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

5.  beta-Adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

6.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  C R Kumana
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

8.  Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease.

Authors:  J W Lammers; H T Folgering; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

9.  Assessment of beta-adrenoceptor antagonists in asthmatic patients.

Authors:  R E Ruffin; E L McIntyre; K M Latimer; H E Ward; A J Crockett; J H Alpers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 10.  Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Authors:  Khaled Albouaini; Mohammed Andron; Albert Alahmar; Mohaned Egred
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.